• Journal of Hospice and Palliative Care
• /
• 제17권2호
• /
• pp.85-89
• /
• 2014

유방암 환자의 흉막 전이는 흔한 소견이다. 흉수가 가장 흔한 증상이고 흉수를 동반하지 않는 흉막 결절이나 흉막 판은 비교적 드물다. 본 환자는 말기 유방암으로 인해 흉수를 동반하지 않는 빠른 속도로 악화되는 거대 흉막 종양이 생겨났고 그로 인해 심한 호흡곤란을 경험했던 환자로 보기 드문 증례로서 보고를 하며 이와함께 말기암환자의 호흡곤란의 치료에 대해 고찰해 보고자 한다.

• Journal of Chest Surgery
• /
• 제53권3호
• /
• pp.114-120
• /
• 2020

Background: Evidence is lacking on whether the resection of lung parenchymal cancer improves the survival of patients with unexpected pleural metastasis encountered during surgery. We conducted a single-center retrospective study to determine the role of lung resection in the long-term survival of these patients. Methods: Among 4683 patients who underwent lung surgery between 1995 and 2014, 132 (2.8%) had pleural metastasis. After excluding 2 patients who had incomplete medical records, 130 patients' data were collected. Only a diagnostic pleural and/or lung biopsy was performed in 90 patients, while the lung parenchymal mass was resected in 40 patients. Results: The mean follow-up duration was 29.8 months. The 5-year survival rate of the resection group (34.7%±9.4%) was superior to that of the biopsy group (15.9%±4.3%, p=0.016). Multivariate Cox regression analysis demonstrated that primary tumor resection (p=0.041), systemic treatment (p<0.001), lower clinical N stage (p=0.018), and adenocarcinoma histology (p=0.009) were significant predictors of a favorable outcome. Interestingly, primary tumor resection only played a significant prognostic role in patients who received systemic treatment. Conclusion: When pleural metastasis is unexpectedly encountered during surgical exploration, resection in conjunction with systemic treatment may improve long-term survival, especially in adenocarcinoma patients without lymph node metastasis.

• 대한영상의학회지
• /
• 제85권3호
• /
• pp.631-636
• /
• 2024

흉막 전이는 흉막에 생기는 악성 질환 중 가장 흔한 원인으로 주로 흉수, 흉막의 결절, 흉막 비후 등의 소견을 보인다. 한편, 흉막폐실질 탄력섬유증(pleuroparenchymal fibroelastosis; 이하 PPFE)은 폐 첨부의 흉막과 주변 폐 실질의 섬유화를 특징으로 하는 질환이다. 저자들은 폐의 양 첨부에 기저 PPFE와 함께 좌하엽에 위치하는 원발성 폐암의 좌측 첨부 흉막 전이가 동반되었던 60세 남자 환자의 증례를 보고한다. 흉막 전이로 인한 좌측 첨부의 비대칭적인 흉막 비후 소견이 진단 초기에 기저 PPFE 병변으로 오인되었다. 또한 PPFE의 MRI 소견을 포함한 영상 소견 및 조직병리학적 소견을 함께 기술하였다.

• 대한한방내과학회지
• /
• 제42권3호
• /
• pp.420-430
• /
• 2021

The survival time of breast cancer patients with lung metastasis has been prolonged as treatment methods have improved. However, there is yet no definitive therapy for the additional symptoms of lung metastasis to improve the quality of life of these patients. We report a patient who was suffering from pleural effusion due to metastasized breast cancer. She was treated with Korean medicine, including herbal medicine (Bojungikgi-tang-gami), combined with hormone therapy, for two months. We assessed her other symptoms, such as shortness of breath, generalized weakness, and lower extremity swelling, using a numeric rating scale (NRS). We also evaluated pleural effusion with chest X-rays. Shortness of breath was maintained at NRS 5, generalized weakness was slightly improved from NRS 6~7 to NRS 7~8 (10=healthy condition), and lower extremity edema was improved from NRS 3 to NRS 2 (10=highest score of discomfort). Malignant pleural effusion was maintained during the admission period. This report suggests that Korean medicine can help to maintain malignant pleural effusion and improve additional symptoms of lung metastasis.

• Tuberculosis and Respiratory Diseases
• /
• 제70권1호
• /
• pp.74-78
• /
• 2011

Herein, we report a case of recurrent pleural metastasis after complete resection of invasive thymoma that was successfully treated with surgical resection. Thymoma and thymic carcinoma are uncommon neoplasms derived from the epithelial cells of the thymus. Approximately 30% to 50% of thymomas are asymptomatic at the time of diagnosis. However, these cancers may present with constitutional or local pressure symptoms and sometimes with paraneoplastic syndromes, especially myasthenia gravis. Surgical resection is the mainstay of thymoma treatment and has been shown to remarkably improve long-term survival. Despite complete resection, local recurrences are frequent, and surgery is the cornerstone of therapy even in cases of recurrent thymoma. We experienced a 67-year-old male patient with pleural metastasis that developed 6 years after complete surgical resection of invasive thymoma. The pleural mass was excised by video-assisted thoracoscopic surgery. Histopathological examination revealed an invasive World Health Organization (WHO) type B2 thymoma.

• Tuberculosis and Respiratory Diseases
• /
• 제57권3호
• /
• pp.289-291
• /
• 2004

Malignant melanoma develops from melanocytes and frequently metastases to other organs. Common metastatic sites are other skin, lymph nodes, lung, liver, brain and bone in decreasing order of frequency. Malignant pleural effusion is less frequent manifestation of thoracic metastasis. We experienced a 57-year-old man with pleural effusion who received radical resection with local flap on left foot due to acral lentiginous melanoma 3 years ago. He had progressive chest pain and left massive pleural effusion. The pleural cytology and biopsy showed malignant melanoma. After closed thoracostomy and talc pleurodesis, he refused further immunotherapy and chemotherapy and discharged.

• Tuberculosis and Respiratory Diseases
• /
• 제42권4호
• /
• pp.594-599
• /
• 1995

저자들은 젊은 남자에서 잠재성 유두상 갑상선암이 흉막전이되어 호흡곤란을 유발할 정도의 대량 흉수로 발현된 증례에서 전갑상선절제술로 원발 종양을 병리학적으로 확인하고 악성흉수에 대한 흉막유착술과 전이성 유두양 갑상선암에 대한 방사선 옥소치료를 시행한 증례를 경험하였기에 문헌고찰과 함께 보고하는 바이다.

• Journal of Chest Surgery
• /
• 제53권5호
• /
• pp.317-320
• /
• 2020

Pulmonary carcinoids are relatively rare tumors with low metastatic potential. Pleural carcinomatosis of a bronchial carcinoid has only been reported in 4 cases. Due to the rarity of this condition, there are no guidelines for its treatment or management. We report a case of atypical carcinoid with local recurrence and pleural metastases treated by video-assisted thoracoscopic surgery lobectomy and total pleurectomy with photodynamic therapy after non-radical wedge resection.

• Journal of Chest Surgery
• /
• 제37권4호
• /
• pp.382-385
• /
• 2004

Non-typhoid salmonella감염질환은 악성 종양, 당뇨병, 스테로이드의 장기사용 등 면역 기능이 저하된 환자에서 흔히 균혈증과 동반되어 드물게 보고되고 있다. 그중에 non-typhoid salmonella에 의한 농흉과 심낭염의 합병 발생은 극히 드물다. 저자들은 흉막 전이가 동반된 악성 흉선종 환자에서 Group D salmonella 감염으로 인한 농흉과 심낭염이 합병되었던 예를 치험하였기에 문헌 고찰과 함께 보고한다.

• 항공우주의학회지
• /
• 제31권2호
• /
• pp.57-59
• /
• 2021

For nonsmall cell lung cancer (NSCLC), surgery is indicated only for stage 3 as a curative measure. Even so, there is a high risk of recurrence following stage 3 lung cancer surgery, a third (33.9%) of patients experienced a cancer recurrence mostly within 2 years after surgery. The median survival time for all stages reaches only 21.9 months. For people undergoing surgery for stage 3A NSCLC, a pre-operative course of (neoadjuvant chemotherapy) can improve survival times, by improving the resectability and lowering the risk of recurrence. Pleural metastases are frequently associated with tumors of the lung and breast. Chest radiographs and computed tomography scans of pleural metastases can present as an effusion or smooth or nodular pleural thickening. In the absence of irregular or nodular pleural thickening, it is difficult to distinguish a benign from a malignant pleural effusion. To treat lung cancer, tyrosine kinase inhibitors (TKIs) recently have been used to cope with genetic mutations, apart from cytotoxic anticancer drugs. Compared to cytotoxic drugs, they are effective, have fewer side effects, and are easy to administer. Airman must have no cancer disease to apply for Class-I medical certification. Specifically, if previously operated on cancer, the cancer should not remain in the body at present, and the disease free state should persist at least one year after all kinds of anti-cancer treatments including adjuvant chemotherapy are completed. Here, this case deals with a 41-year-old pilot who has ATP license who had stage 3A NSCLC. The pilot underwent curative lung cancer surgery (lobectomy) a year ago and showed suspicious pleural metastasis at the time of his application for certification and was still using an unauthorized TKI agent alectinib (Alecensa; Roche, Basel, Switzerland).